ArticleAdvances in therapy2022
Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study.
Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Expert consensus on osteoporosis risk management in patients with sleep disorders.Bone research · 2026Review
- Health and economic burden of insomnia medications among older Americans: findings from the future elderly model.Lancet regional health. Americas · 2026Article
- Off-label policy through the lens of trazodone usage and spending in the United States.Health affairs scholar · 2025Article
- Abnormal sensory processing cortex in insomnia disorder: a degree centrality study.Brain imaging and behavior · 2025Observational
- Real-world data on the abuse potential of medications for the treatment of insomnia: a disproportionality analysis of the FAERS database.Frontiers in pharmacology · 2025Article
- Cost Savings Associated With Fully Automated Digital Cognitive Behavioral Therapy for Insomnia Disorder (SleepioRx): A Matched Control Study of US Patients.Journal of health economics and outcomes research · 2025Article
- Switching to lemborexant for the management of insomnia in mental disorders: the SLIM study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Article
- Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal.Journal of clinical medicine · 2023Review
- Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2022Review
- Demographics and clinical characteristics of patients of prescribing psychologists, psychiatrists, and primary care physicians.The American psychologistArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFalls are a common cause for morbidity and mortality among patients taking prescription insomnia medication. The objective of this study is to compare the risk of falls, all-cause healthcare resource utilization (HCRU), and costs among patients treated with commonly used, older generation insomnia medications and non-sleep-disordered controls.
methodsThis retrospective cohort study used the IBM
resultsRelative to matched controls (n = 313,086), the insomnia-treated cohort had a higher rate of falls (3.34% vs. 1.33%), and higher risk of falls [OR = 2.36 (95% confidence interval 2.27-2.44)]. Relative to other index treatments, patients treated with trazodone had the greatest risk of falls. Compared with matched controls, the estimated mean number of inpatient visits, emergency department visits, outpatient visits, and mean length of inpatient stay were all significantly higher among patients treated for insomnia. Such patients incurred greater total costs per patient per month than matched controls ($2100 versus $888; estimated mean ratio, 2.36; 95% CI 2.35-2.38; p < 0.0001).
conclusionsRelative to matched controls, the insomnia-treated cohort showed higher risk of falls with greater HCRU and costs. Each outcome measured was highest among patients treated with trazodone, relative to other index treatments. Findings suggest the need for new treatment options to optimize quality of care for patients with insomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.